GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cumberland Pharmaceuticals Inc (NAS:CPIX) » Definitions » EBIT

Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) EBIT : $-5.62 Mil (TTM As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is Cumberland Pharmaceuticals EBIT?

Cumberland Pharmaceuticals's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-6.10 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-5.62 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cumberland Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 was -41.47%. Cumberland Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -345.23%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cumberland Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -23.27%.


Cumberland Pharmaceuticals EBIT Historical Data

The historical data trend for Cumberland Pharmaceuticals's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cumberland Pharmaceuticals EBIT Chart

Cumberland Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9.05 -6.31 -5.46 -5.00 -5.62

Cumberland Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.23 0.37 1.06 -0.95 -6.10

Competitive Comparison of Cumberland Pharmaceuticals's EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Cumberland Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cumberland Pharmaceuticals's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cumberland Pharmaceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cumberland Pharmaceuticals's EV-to-EBIT falls into.



Cumberland Pharmaceuticals EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cumberland Pharmaceuticals  (NAS:CPIX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cumberland Pharmaceuticals's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-24.716 * ( 1 - -0.4% )/( (62.491 + 57.197)/ 2 )
=-24.814864/59.844
=-41.47 %

where

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Cumberland Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-24.392/( ( (7.089 + max(-3.732, 0)) + (7.042 + max(-10.242, 0)) )/ 2 )
=-24.392/( ( 7.089 + 7.042 )/ 2 )
=-24.392/7.0655
=-345.23 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.62 + 8.671 + 1.971) - (10.818 + 0 + 16.176)
=-3.732

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(9.758 + 4.609 + 3.025) - (16.847 + 0.22 + 10.567)
=-10.242

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cumberland Pharmaceuticals's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-5.616/24.136
=-23.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cumberland Pharmaceuticals EBIT Related Terms

Thank you for viewing the detailed overview of Cumberland Pharmaceuticals's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cumberland Pharmaceuticals (Cumberland Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
1600 West End Avenue, Suite 1300, Nashville, TN, USA, 37203
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, RediTrex, Sancuso, Vaprisol and Vibativ.
Executives
Todd M. Anthony officer: Vice Pres Organizational Dev 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Chris T. Bitterman officer: Vice Pres Sales & Marketing 1600 WEST END AVENUE, SUITE 1300, NASHVILLE TN 37203
Joseph C Galante director 111 TENTH AVENUE, SUITE 200, NASHVILLE TN 37203
James Jones director 2525 WEST END AVE., SUITE 950, NASHVILLE TN 37203
Kenneth Krogulski director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Caroline Young director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Brown Martin S Jr director 850 DIXIE HIGHWAY, LOUISVILLE KY 40210
A J Kazimi director, 10 percent owner, officer: Chairman and CEO 1207 17TH AVENUE SUITE 103, NASHVILLE TN 37212
Martin E Cearnal director 31 UPPER MOUNTAIN AVENUE, APARTMENT 2, MONTCLAIR NJ 07042
John M. Hamm officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Gordon R Bernard officer: Senior Vice President 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Joey A Jacobs director 830 CRESCENT CENTER DRIVE, SUITE 610, FRANKLIN TN 37067
Michael Bonner officer: Chief Financial Officer 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Jonathan Griggs director 2525 WEST END AVENUE, SUITE 950, NASHVILLE TN 37203
Thomas R Lawrence director 1880 ELLINGTON WAY, AUBURN AL 36830